PGF and neoplasm: In this regard, TB-403 (RO5323441), a humanized recombinant IgG1 monoclonal antibody, directed to the receptor-binding site of PlGF, has demonstrated that targeting PlGF can result in significant inhibition of tumor growth and metastasis in preclinical studies.